A comprehensive view of Elanco Animal Health Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Pet Care Market Intelligence Service.
Stifel upgrades Elanco Animal Health to buy, predicts its stock could rise another 27%, on top of 80% gain over past two months; significant revenue growth expected until 2025, bolstered by canine treatments such as Zenrelia and Quattro
Published:
January 05, 2024
by Invezz
|
Elanco Animal Health's Bexacat product wins Overall Cat Health Product of the Year at Pet Innovation Awards for improving glycemic control in diabetic cats; as first oral prescription tablet of its kind, Bexacat eliminates need for insulin injections
Published:
November 02, 2023
by GlobeNewswire
|
Ask us about our Pet Care market view